|
|
||||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
1 Research Division, Manhattan State Hospital, Ward's Island, New York 35, N. Y.
Propericiazine (SK&F 20,716) was effective in the treatment of severe be havioral disorders in nine of 17 patients who were previously refractory to other medication. The dose range was 75 to 600 mg. daily. Side reactions were mild and offered no difficulty in management. Controlled trials would now appear warranted.
Note:
This study was supported in part by Grant MH-05093-03, Department of Health, Education, and Welfare, National Institutes of Health, Bethesda, Md.
The authors acknowledge with thanks the assistance rendered by Dr. John E. Overall, Director, Research Computation Center, The University of Texas-Medical Branch, Galveston, Texas.
Propericiazine was furnished through the kind co-operation of Mr. Donald B. Cheetham, Jr., Research Associate, Smith Kline & French Laboratories, Philadelphia, Pa.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |